The status of liver transplantation for hepatitis C

Andrew M Cameron, Ronald W. Busuttil

Research output: Contribution to journalArticle

Abstract

The hepatitis C virus (HCV) infects 3% of the world's population, or ∼170 million people. Most of those acutely infected progress to chronic infection and are unresponsive to existing antiviral treatment. Over a 20-year period, chronic HCV infection leads to cirrhosis and the sequelae of end-stage liver disease, including hepatic encephalopathy, ascites, variceal haemorrhage and hepatocellular carcinoma. Orthotopic liver transplantation (OLT) is the optimal treatment for decompensated HCV cirrhosis, but is limited by organ availability and universal graft reinfection. This review discusses the results with OLT for HCV from the Dumont-UCLA Liver Transplant Center and discusses future directions in the management of HCV.

Original languageEnglish (US)
Pages (from-to)993-1002
Number of pages10
JournalExpert Opinion on Biological Therapy
Volume6
Issue number10
DOIs
StatePublished - Oct 2006
Externally publishedYes

Fingerprint

Hepatitis C
Viruses
Hepacivirus
Liver
Liver Transplantation
Fibrosis
Transplants
End Stage Liver Disease
Hepatic Encephalopathy
Chronic Hepatitis C
Virus Diseases
Ascites
Grafts
Antiviral Agents
Hepatocellular Carcinoma
Availability
Hemorrhage
Therapeutics
Infection
Population

Keywords

  • Hepatitis C virus
  • Hepatocellular carcinoma
  • Orthoropic liver transplantation

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology

Cite this

The status of liver transplantation for hepatitis C. / Cameron, Andrew M; Busuttil, Ronald W.

In: Expert Opinion on Biological Therapy, Vol. 6, No. 10, 10.2006, p. 993-1002.

Research output: Contribution to journalArticle

@article{242288c381f14aaba79495bc7986dace,
title = "The status of liver transplantation for hepatitis C",
abstract = "The hepatitis C virus (HCV) infects 3{\%} of the world's population, or ∼170 million people. Most of those acutely infected progress to chronic infection and are unresponsive to existing antiviral treatment. Over a 20-year period, chronic HCV infection leads to cirrhosis and the sequelae of end-stage liver disease, including hepatic encephalopathy, ascites, variceal haemorrhage and hepatocellular carcinoma. Orthotopic liver transplantation (OLT) is the optimal treatment for decompensated HCV cirrhosis, but is limited by organ availability and universal graft reinfection. This review discusses the results with OLT for HCV from the Dumont-UCLA Liver Transplant Center and discusses future directions in the management of HCV.",
keywords = "Hepatitis C virus, Hepatocellular carcinoma, Orthoropic liver transplantation",
author = "Cameron, {Andrew M} and Busuttil, {Ronald W.}",
year = "2006",
month = "10",
doi = "10.1517/14712598.6.10.993",
language = "English (US)",
volume = "6",
pages = "993--1002",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - The status of liver transplantation for hepatitis C

AU - Cameron, Andrew M

AU - Busuttil, Ronald W.

PY - 2006/10

Y1 - 2006/10

N2 - The hepatitis C virus (HCV) infects 3% of the world's population, or ∼170 million people. Most of those acutely infected progress to chronic infection and are unresponsive to existing antiviral treatment. Over a 20-year period, chronic HCV infection leads to cirrhosis and the sequelae of end-stage liver disease, including hepatic encephalopathy, ascites, variceal haemorrhage and hepatocellular carcinoma. Orthotopic liver transplantation (OLT) is the optimal treatment for decompensated HCV cirrhosis, but is limited by organ availability and universal graft reinfection. This review discusses the results with OLT for HCV from the Dumont-UCLA Liver Transplant Center and discusses future directions in the management of HCV.

AB - The hepatitis C virus (HCV) infects 3% of the world's population, or ∼170 million people. Most of those acutely infected progress to chronic infection and are unresponsive to existing antiviral treatment. Over a 20-year period, chronic HCV infection leads to cirrhosis and the sequelae of end-stage liver disease, including hepatic encephalopathy, ascites, variceal haemorrhage and hepatocellular carcinoma. Orthotopic liver transplantation (OLT) is the optimal treatment for decompensated HCV cirrhosis, but is limited by organ availability and universal graft reinfection. This review discusses the results with OLT for HCV from the Dumont-UCLA Liver Transplant Center and discusses future directions in the management of HCV.

KW - Hepatitis C virus

KW - Hepatocellular carcinoma

KW - Orthoropic liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=33749362060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749362060&partnerID=8YFLogxK

U2 - 10.1517/14712598.6.10.993

DO - 10.1517/14712598.6.10.993

M3 - Article

VL - 6

SP - 993

EP - 1002

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 10

ER -